Overview
Top Medical Research Studies
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
Key predictors included a history of thromboembolism and bleeding, low time in therapeutic range, and reduced kidney function. Notably, while VKAs are crucial, they come with risks that we need to monitor closely to improve patient outcomes.
Most Useful Reviews
Medical Researches
- All Researches
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
In our analysis of a randomized clinical trial, we compared apixaban, a novel anticoagulant, to vitamin K antagonists and evaluated the overall safety and efficiency of these treatments.
Our results showed that apixaban effectively reduced major bleeding events without increasing ischemic risks compared to vitamin K. We recommend using apixaban with a low-potency P2Y inhibitor as the standard care approach.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
User Reviews
- All Reviews
- Positive Reviews
- Negative Reviews
Frequently Asked Questions
A blood clot is a mass of blood that changes from a liquid to a gel, effectively forming a plug that can stop bleeding. This natural process, known as coagulation, is critical for preventing excessive blood loss when you sustain an injury. Blood clots can occur in various areas of the body, typically at the site of a wound, but they can also form within blood vessels without an obvious injury, which may lead to serious health complications.
While blood clots are essential for healing, they can pose significant health risks if they form inappropriately. For example, a deep vein thrombosis (DVT) occurs when a clot forms in a deep vein, usually in the legs, and can travel to the lungs, causing a life-threatening condition called a pulmonary embolism. Risk factors for blood clots include prolonged immobility, certain medical conditions, and the use of specific medications, among others. It’s important to recognize the symptoms of abnormal clotting, such as swelling, pain, and redness in the affected area, and seek medical attention if they occur.
Vitamin K is a fat-soluble vitamin crucial for various bodily functions, particularly in the clotting process of blood. It exists in two primary forms: K1 (phylloquinone), which is primarily found in leafy green vegetables like spinach and kale, and K2 (menaquinone), which is found in fermented foods and certain animal products. Vitamin K plays a significant role in the synthesis of proteins that regulate blood coagulation and is also essential for bone metabolism, assisting in the binding of calcium to bones and other tissues.
Deficiencies in vitamin K can lead to increased bleeding and bruising, and in severe cases, it may contribute to bone weakness. While most people can obtain adequate amounts of vitamin K through a balanced diet rich in vegetables and fermented foods, those with certain medical conditions or who are on specific medications may require monitoring and supplementation. Incorporating a variety of nutrient-dense foods into your diet is the best way to ensure you get enough vitamin K for optimal health.
Vitamin K plays a crucial role in the body's blood clotting process, making it essential for maintaining proper vascular health. It supports the synthesis of certain proteins known as clotting factors, which are vital for blood coagulation. When an injury occurs, these proteins help form a clot to stop bleeding. Thus, an adequate intake of Vitamin K can be beneficial in situations where blood clotting needs to occur, like in response to a wound or surgery.
However, it's important to note that while Vitamin K is essential for normal clotting, it should be approached cautiously, especially for individuals on anticoagulant medications (like warfarin), which work by inhibiting Vitamin K's action. If you are considering changes to your Vitamin K intake or have concerns regarding blood clotting, it is always advisable to consult a healthcare professional for tailored advice.
Based on user reviews, many individuals report experiencing noticeable improvements in blood clotting within a few days to a few weeks after starting the supplement. For instance, one user indicated that they observed remarkable effects just a few days after beginning the vitamins, and a follow-up test after three weeks confirmed their blood clotting had returned to normal levels (Read Review). Similarly, other users noted enhanced healing of minor cuts and bruises after a few weeks of use, suggesting an improvement in clotting efficiency during that time frame (Read Review).
Scientific research supports the use of specific supplements, particularly vitamin K antagonists (VKAs), in managing blood clots effectively. A multicenter study highlighted that VKAs, such as warfarin, were used to treat left ventricular thrombosis, resulting in about 70% of patients experiencing resolution of their blood clots [2]. Furthermore, feedback from clinical use suggests that VKAs have a balanced safety profile, contributing to successful clot management with minimal severe complications [1]. This indicates that VKAs can play a crucial role in blood clot resolution.
Additionally, research comparing VKAs to newer oral anticoagulants shows that while VKAs have been effective, the newer agents like apixaban and rivaroxaban demonstrated better clot-clearing results without increasing adverse events [11]. However, VKAs continue to be a cornerstone in anticoagulation therapy, particularly in patients with specific conditions like antiphospholipid syndrome [3]. In summary, while VKAs have historical efficacy in the treatment of blood clots, newer alternatives may offer improved outcomes, emphasizing the importance of therapy personalization based on patient conditions.
Users report a variety of improvements in symptoms related to blood clotting after starting these supplements. Many have noticed significant enhancements in their healing processes, particularly with minor cuts and bruises, indicating faster recovery times. For instance, one user expressed that their healing improved dramatically within only a few days of beginning the supplement, with a subsequent blood test confirming that their clotting levels returned to normal after three weeks (Read Review). This sentiment is echoed by others who mentioned better management of injuries, suggesting an overall improvement in clotting efficiency after consistent use (Read Review).
Additionally, users highlight that the combination of vitamins K1 and K2 supports not only blood clotting but also bone health and cardiovascular function, providing a dual benefit from the supplement (Read Review). Some individuals are particularly satisfied with the vitamin's impact on their overall well-being, reporting that it acts as an excellent addition to their health regimen (Read Review). However, it's important to note that individual results can vary, and users are encouraged to consult with healthcare professionals before starting any new supplement regimen.
Users have reported positive experiences when combining this supplement with other vitamins, particularly in relation to blood clot management. Many reviewers highlighted the synergy between vitamins K1 and K2, noting their combined effect not only on blood clotting but also on bone health and cardiovascular function. One user mentioned the effectiveness of taking vitamin K alongside other nutrients, stating, "The blend of vitamins K1 and K2, along with vitamins D and minerals, promotes healthy blood clotting" (Read Review). This dual benefit seemed to enhance overall well-being and resulted in faster healing of minor cuts and bruises for users (Read Review).
Moreover, several users specifically referred to the importance of maintaining a balanced regimen, suggesting that consulting with a healthcare professional before starting this supplement, particularly if one is prone to deficiencies or health issues related to blood clotting, is a prudent step. For instance, one review pointed out the potential necessity of discussing this vitamin complex with a doctor before implementation (Read Review). Overall, the combination appears to support better health outcomes, but individual results may vary depending on existing health conditions and dietary habits.
Based on user reviews, there seems to be a consensus that vitamin K is essential for blood clotting, with many users reporting significant improvements in their clotting issues after incorporating vitamin K supplements into their routines. One user noted a rapid change in their healing process, stating that their clotting levels returned to normal within three weeks of supplementation, which underlines the effectiveness of these vitamins in addressing clotting deficiencies (Read Review). Another review highlighted how vitamins K1 and K2 work synergistically, with K1 being particularly crucial for blood clotting and K2 enhancing calcium metabolism, further supporting cardiovascular and bone health (Read Review).
Users often recommend consulting a healthcare professional before starting any supplementation regimen, particularly for determining the appropriate dosage of vitamin K (Read Review). The reviews suggest that regular intake of vitamin K, especially in its K2 form, can be beneficial for maintaining optimal blood clotting and overall health (Read Review). Overall, while specific dosage recommendations can vary, the importance of vitamin K in promoting effective blood clotting is well-supported among users.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
In a case study with two women suffering from APS, we noted that point-of-care testing often showed misleadingly high INR results. This could lead to inappropriate dosing of VKAs and a higher chance of recurrent clots.
However, our findings suggest that by developing individualized correction factors, we could enhance the accuracy of these tests, helping improve VKA management and patient safety.
References
- Karkouti K, Gareis M, Li C, Brandstätter H, Pichotta A, et al. Twenty years of the four-factor prothrombin complex concentrate Octaplex/Balfaxar: A narrative review. Transfus Apher Sci. 2025;64:104115. doi:10.1016/j.transci.2025.104115
- Valeriani E, Astorri G, Pannunzio A, Pastori D, Palumbo IM, et al. Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study. Intern Emerg Med. 2025. doi:10.1007/s11739-025-03922-6
- Geertsema-Hoeve BC, Radin M, Sciascia S, Urbanus RT, Huisman A, et al. Problem Solved? An Individual Ratio between Point-of-Care and Venous International Normalized Ratio Values in Two Patients with Antiphospholipid Syndrome: Two Case Reports. TH Open. 2025;9:a25425358. doi:10.1055/a-2542-5358
- Last J, Birschmann I, Lindau S, Konstantinides S, Grottke O, et al. Anticoagulant Management After Emergency Surgery or Major Bleeding in Anticoagulated Patients-Results of the Prospective RADOA Registry. Pharmaceuticals (Basel). 2025;18. doi:10.3390/ph18020170
- van de Munckhof A, van Kammen MS, Tatlisumak T, Krzywicka K, Aaron S, et al. Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study. Lancet Neurol. 2025;24:199. doi:10.1016/S1474-4422(24)00519-2
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. doi:10.36660/abc.20240147
- Hall EH, Sølsnes MH, Sandberg S, Sølvik UØ. Patient self-management of warfarin therapy - a long-term follow up study. Thromb J. 2025;23:14. doi:10.1186/s12959-025-00694-z
- Liu Y, Lam SHM, Romiti GF, Huang B, Chen Y, et al. Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III. J Thromb Thrombolysis. 2025;58:165. doi:10.1007/s11239-025-03067-5
- Tannu M, Lopes RD, Wojdyla DM, Goodman SG, Aronson R, et al. Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS. J Am Coll Cardiol. 2025;85:1157. doi:10.1016/j.jacc.2024.10.125
- Zorman MJ, Vibhishanan J, Dangas K, Castle J, Li KHC, et al. Valve Thrombosis and Antithrombotic Therapy After Bioprosthetic Mitral Valve Replacement: A Systematic Review And Meta-Analysis. Eur Heart J Cardiovasc Pharmacother. 2025. doi:10.1093/ehjcvp/pvaf005
- Mo GL, Wen J, Ye YY, Lu YQ, Gan TM, et al. Efficacy and Safety of New Oral Anticoagulants versus Warfarin in the Resolution of Atrial Fibrillation with Left Atrial/Left Atrial Appendage Thrombus: A Systematic Review and Meta-Analysis. Rev Cardiovasc Med. 2025;26:26055. doi:10.31083/RCM26055
- Kempers EK, Visser C, Geijteman ECT, Goedegebuur J, Portielje JEA, et al. Discontinuation of Anticoagulants and Occurrence of Bleeding and Thromboembolic Events in Vitamin K Antagonist Users with a Life-limiting Disease. Thromb Haemost. 2025. doi:10.1055/a-2524-5334
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. doi:10.1136/openhrt-2024-002966
- Mapelli M, Celeste F, Maiolo G, Mancini E, Agostoni P. Incidental Diagnosis of Massive Mobile Left Ventricle Thrombi Following COVID-19 in a Heart Failure Patient. JACC Case Rep. 2024;29:102870. doi:10.1016/j.jaccas.2024.102870
- Gustafsson F, Uriel N, Netuka I, Katz JN, Pagani FD, et al. Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial. JAMA Cardiol. 2025;10:235. doi:10.1001/jamacardio.2024.4849
- Premkumar M, Bhujade H, Sharma P, Nain J, Ahluwalia J, et al. Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival. Aliment Pharmacol Ther. 2025;61:971. doi:10.1111/apt.18474
